Asia Pacific
Refine Search
Pharmaceutical
Japanese drugmaker Otsuka Pharmaceutical and its US subsidiary have decided to terminate the development of the novel compound AVP-786, which was being studied as a potential treatment for patients with agitation associated with dementia due to Alzheimer's disease. 23 May 2024
Biotechnology
Given that the USA’s House Committee on Oversight and Accountability held a markup meeting last week on the legislation, it is likely that the USA will pass the BIOSECURE Act (the Act) in December this year. 21 May 2024
Biotechnology
UK pharma major AstraZeneca today revealed it intends to build a $1.5 billion manufacturing facility in Singapore for antibody-drug conjugates (ADCs), enhancing global supply of its ADC portfolio. 20 May 2024
Pharmaceutical
Japanese drugmaker Otsuka has announced that the primary endpoint was achieved in the Phase III trial in Japan of bempedoic acid as a potential treatment for patients with hypercholesterolemia. 20 May 2024
Generics
The Japan generic drug market size reached $11.5 billion in 2023 and is forecast to see strong growth. 20 May 2024
Biotechnology
Shares of HLB Pharma plunged almost 30% to 67,100 won on Friday to their daily price floors, as the US Food and Drug Administration (FDA) rejected a new drug approval for rivoceranib, the Korean firm’s liver cancer treatment, according to a Korea Times report. 18 May 2024
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has received supplemental approvals for the BRAF inhibitor Braftovi (encorafenib), and the MEK inhibitor Mektovi (binimetinib), when used in combination, in Japan for two new indications. 17 May 2024
Biotechnology
A well-financed US start-up has in-licensed three obesity drug candidates from Chinese drugmaker Jiangsu Hengrui Pharmaceuticals. 17 May 2024
Biotechnology
The USA’s House Committee on Oversight and Accountability held a markup meeting yesterday to consider a series of bills that address federal agency procurement of biotechnology equipment, safeguarding taxpayer dollars, improving federal cybersecurity, and more. 16 May 2024
Pharmaceutical
Chinese biopharma company Everest Medicines announced that Nefecon, a delayed release capsule of budesonide, has been successfully launched in China with the first prescription issued. 14 May 2024
Pharmaceutical
The Phase III study (SCORPIO-HR) with ensitrelvir did not meet its primary endpoint of a statistically-significant reduction in time to sustained resolution of 15 common COVID-19 related symptoms, said Japanese drugmaker Shionogi. 13 May 2024
Biosimilars
The US unit of South Korea’s Celltrion announced that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to Humira (adalimumab), is now available at a low wholesale acquisition cost (WAC). 13 May 2024
Biosimilars
A new version of a congressional bill, dubbed the BIOSECURE Act, that would restrict US business with certain Chinese biotechnology companies would give US companies until 2032 to end work with the firms, extending the amount of time to find new partners. 11 May 2024
Biotechnology
Privately-held Californian company Maze Therapeutics has found a new partner for its investigational Pompe disease candidate in the form of Japan’s Shionogi. 11 May 2024
Pharmaceutical
China’s Innovent Biologics has presented impressive results on mazdutide, its dual GLP-1/glucagon receptor agonist partnered with US pharma major Eli Lilly. 10 May 2024
Biotechnology
Shares of USA-based tumor drug resistance specialist Deciphera Pharmaceuticals soared 73% to $25.34 in morning trading, on the news that it has received a takeover bid. 8 May 2024
Biotechnology
Research from industry analyst GlobalData finds that Chinese companies are leading in the development of antibody-drug conjugates (ADC). 7 May 2024
Biotechnology
The prestigious New England Journal of Medicine (NEJM) has published interim results from the Phase III trial of Japanese drug major Takeda Pharma’s Adzynma (apadamtase alfa/cinaxadamtase alfa; code name TAK-755) in patients with congenital thrombotic thrombocytopenic purpura (cTTP). 5 May 2024
Biosimilars
The biopharmaceutical industry has been buzzing over the US government's unveiling of the BIOSECURE bill. 3 May 2024
Generics
The COVID-19 pandemic has underscored the vulnerabilities inherent in global supply chains, particularly those predicated on single-country reliance. 2 May 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
Anglo-American biotech Apollo Therapeutics and China-based Sunshine Lake Pharma have signed an exclusive license agreement to develop APL-18881, a bi-specific fusion protein aimed at treating metabolic diseases. 13 November 2024
Biotechnology
Dutch firm Argenx and China’s Zai Lab have received an approval from the National Medical Products Administration (NMPA) for Vyvgart Hytrulo (efgartigimod alfa). 13 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Sino-American oncology company BeiGene has announced third-quarter 2024 financials, showing the total revenues was $1,002 million, up 28% compared to $781 million in the same period of 2023. 13 November 2024
Pharmaceutical
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices. 11 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze